Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood

Prather, William R.; Toren, Amir; Meiron, Moran

doi:10.1517/14712598.8.8.1241

Cited by 38 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding interactions with other stem-cell types, PDSCs may exhibit superior engraftment properties than BM-MSCs due to a more efficient utilization of VL4-mediated binding [82]. Specific derivatives of human placenta-expanded MSCs designated as PLX-I also seem to enhance the engraftment of HSCs [83].…”

Section: Placenta Stem Cellsmentioning

confidence: 99%

Novel Sources of Fetal Stem Cells: Where do they Fit on the Developmental Continuum?

2009

View full text Add to dashboard Cite

The recent isolation of fetal stem cells from several sources either at the early stages of development or during the later trimesters of gestation, sharing similar growth kinetics and expressing pluripotency markers, provides strong support to the notion that these cells may be biologically closer to embryonic stem cells, actually representing intermediates between embryonic stem cells and adult mesenchymal stem cells, regarding proliferation rates and plasticity features, and thus able to confer an advantage over postnatal mesenchymal stem cells derived from conventional adult sources such as bone marrow. This conclusion has been strengthened by the different pattern of growth potential between the two stage-specific types of sources, as assessed by transcriptomic and proteomic analysis. A series of recent studies regarding the numerous novel features of fetal stem cells has reignited our interest in the field of stem-cell biology and in the possibilities for the eventual repair of damaged organs and the generation of in vitro tissues on biomimetic scaffolds for transplantation. These studies, employing elegant approaches and novel technologies, have provided new insights regarding the nature and the potential of fetal stem cells derived from placenta, amniotic fluid, amnion or umbilical cord. In this update, we highlight the major progression that has occurred in fetal stem-cell biology and discuss the most important areas for future investigation in the field of regenerative medicine.

show abstract

Section: Placenta Stem Cellsmentioning

confidence: 99%

Novel Sources of Fetal Stem Cells: Where do they Fit on the Developmental Continuum?

2009

View full text Add to dashboard Cite

show abstract

“…[14][15][16][17] The minimal criteria for multipotent MSCs defined by the ISCT are as follows: (1) the cells are plastic adherent and when cultured display a spindle fibroblastic-like cell morphology; (2) they have the ability to differentiate toward osteoblasts, adipocytes, and chondrocytes in vitro using specific differentiation inducing stimuli; (3) they have a cell surface expression of CD73, CD90, and CD105 and are negative for CD45, CD34, CD11b, CD14, CD31, CD79, CD19, and MHC class II. 18 Nowadays, clinical applications of MSCs for cellular therapies aim at improved engraftment of hematopoietic stem cell transplantation, [19][20][21] to ameliorate steroid-resistant graft-versus-host disease after allogeneic stem cell transplantation, [22][23][24] treatment of osteogenesis imperfecta, 25,26 and treatment of metabolic disorders, for example, Hurler's disease. 27,28 Another application is in cartilage and bone tissue engineering by combining biomaterials and MSCs.…”

Section: Introductionmentioning

confidence: 99%

Bone-Forming Capacity of Mesenchymal Stromal Cells When Cultured in the Presence of Human Platelet Lysate as Substitute for Fetal Bovine Serum

Prins

Rozemuller

Vonk-Griffioen

et al. 2009

Tissue Engineering Part A

View full text Add to dashboard Cite

In tissue engineering, strategies are being developed to repair large bone defects by combining biomaterials and bone marrow-derived multipotent mesenchymal stromal cells (MSCs). For expansion of MSCs under good manufacturing practice conditions, human platelet lysate (PL) can serve as substitute for fetal bovine serum (FBS) in culture media. We compared the in vivo bone-forming capacity of passage 3 MSCs cultured with either PL or FBS for nine different human donors. We also tested the growth kinetics, antigen expression profile, and the multilineage differentiation capacity in vitro of these MSCs. The in vivo bone-forming capacity was determined by seeding culture-expanded MSCs onto biphasic calcium phosphate scaffolds. Hybrid constructs were implanted subcutaneously in nude mice, retrieved after 6 weeks, and analyzed using histomorphometry. PL-supplemented cultures resulted in significantly larger colonies, shorter culture time period, and higher population doublings between P1 and P3 compared to FBS-containing cultures. No differences were observed in antigen expression profiles or differentiation capacities into the osteoblastic, chondrogenic, and adipogenic lineages, qualitatively. In vivo bone formation with PL-supplemented cultures of MSCs was demonstrated in 9/9 donors versus 6/9 for FBS-supplemented cultures. These results warrant the use of PL for ex vivo expansion of human MSCs for bone tissue engineering applications.

show abstract

“…MSCs are capable of improving HSC engraftment and accelerating hematopoietic reconstitution based on the hematopoiesis-supporting ability. 29,30 We demonstrated that MC-and BM-derived MSCs both had similar hematopoiesis-supportive function, indicating that MCs could be considered a promising alternative in the field of HSC transplantation to BM as a source of MSCs.…”

Section: Discussionmentioning

confidence: 93%

Implantation of biomaterial as an efficient method to harvest mesenchymal stem cells

Liu

Wang

2011

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Autologous mesenchymal stem cell (MSC) transplants have been used successfully to treat a number of diseases, and patients undergoing cell transplantation must have stem cells collected before transplantation. In this study, we developed a new method to harvest MSCs. Biomaterials were implanted into the spatium intermuscular of mice hind limbs, and a large number of migrating cells (MCs) were isolated from the transplanted biomaterials. The adherent cells in MCs showed the characteristics of MSCs. Further comparative study demonstrated that the characteristics of MC-MSCs were similar to that of bone marrow (BM)-MSCs, including morphology, phenotype, proliferation potential, multilineage differentiation capacity and hematopoiesis-supportive function. The colony-forming unit-ﬁbroblast frequency of the MCs was equivalent to approximately 20-fold of that of the BM. In addition, a BM transplantation experiment demonstrated that MC-MSCs were derived from the peripheral blood. In conclusion, we successfully establish an efficient method to harvest MSCs, and together with the distinct advantages of this method, such as accessibility and possibility for autologous cell therapy, we conclude that our efficient method may be a promising alternative for clinical application.

show abstract

Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood

Cited by 38 publications

References 38 publications

Novel Sources of Fetal Stem Cells: Where do they Fit on the Developmental Continuum?

Novel Sources of Fetal Stem Cells: Where do they Fit on the Developmental Continuum?

Bone-Forming Capacity of Mesenchymal Stromal Cells When Cultured in the Presence of Human Platelet Lysate as Substitute for Fetal Bovine Serum

Implantation of biomaterial as an efficient method to harvest mesenchymal stem cells

Contact Info

Product

Resources

About